ID

23348

Beschreibung

Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus

Stichworte

Versionen (1)
  1. 02.07.17 02.07.17 -
Rechteinhaber

Genentech, Inc.

Hochgeladen am

2. Juli 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

Englisch

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

1 Formulare  
Patient administration
Beschreibung

Patient administration

Subject Number
Beschreibung

PT

Datentyp

integer

Alias
UMLS CUI [1]
C2348585
Subject Initials:
Beschreibung

PTINIT

Datentyp

text

Alias
UMLS CUI [1,1]
C1997894
UMLS CUI [1,2]
C2986440
Report Date:
Beschreibung

VDT

Datentyp

date

Alias
UMLS CUI [1,1]
C1302584
TREATMENT CROSSOVER (UNSCHEDULED)
Beschreibung

TREATMENT CROSSOVER (UNSCHEDULED)

Did the subject participate in the treatment crossover plan?
Beschreibung

CROSSOVER_PARTICIPAT [CRSRPAR]

Datentyp

boolean

Alias
UMLS CUI [1]
C0150097
Indicate the visit month at which the subject’s treatment crossover was implemented:
Beschreibung

If Yes:

Datentyp

integer

Were both early crossover criteria listed below met?
Beschreibung

If the crossover visit month was prior to the Month 25 visit, complete the following: • Has lost >=10 letters on EDTRS BCVA from Baseline due to DME, as confirmed on >= 2 consecutive scheduled study visits, and • OCT images confirm persistent edema (CFT 250 μm) at the same visits.

Datentyp

boolean

Alias
UMLS CUI [1]
C0242801
Indicate the reason why the subject did not participate in the treatment crossover:
Beschreibung

If No:

Datentyp

integer

Alias
UMLS CUI [1]
C0680251
Other (specify):
Beschreibung

REASON_TREAT_CRSOVR [NCRSVR]

Datentyp

text

Alias
UMLS CUI [1]
C0680251
Zum Seitenanfang zurückkehren

Ähnliche Modelle

TREATMENT CROSSOVER (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Patient administration
PT
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
PTINIT
Item
Subject Initials:
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
VDT
Item
Report Date:
date
C1302584 (UMLS CUI [1,1])
Item Group
TREATMENT CROSSOVER (UNSCHEDULED)
CROSSOVER_PARTICIPAT [CRSRPAR]
Item
Did the subject participate in the treatment crossover plan?
boolean
C0150097 (UMLS CUI [1])
TRT_CRSOVR_IMP_MTH [RXCOMO]
Item
Indicate the visit month at which the subject’s treatment crossover was implemented:
integer
ELIGIBILITY_CRITERIA [ELIGCR]
Item
Were both early crossover criteria listed below met?
boolean
C0242801 (UMLS CUI [1])
Item
Indicate the reason why the subject did not participate in the treatment crossover:
integer
C0680251 (UMLS CUI [1])
REASON_TREAT_CRSOVR [NCRSVR]
Code List
Indicate the reason why the subject did not participate in the treatment crossover:
CL Item
Subject has discontinued study treatment (1)
CL Item
Subject refused to participate in the treatment crossover plan (2)
CL Item
Other (specify): (3)
REASON_TREAT_CRSOVR [NCRSVR]
Item
Other (specify):
text
C0680251 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video